231 related articles for article (PubMed ID: 19860729)
1. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action.
Matts RL; Manjarrez JR
Curr Top Med Chem; 2009; 9(15):1462-78. PubMed ID: 19860729
[TBL] [Abstract][Full Text] [Related]
2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
3. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.
Yun BG; Huang W; Leach N; Hartson SD; Matts RL
Biochemistry; 2004 Jun; 43(25):8217-29. PubMed ID: 15209518
[TBL] [Abstract][Full Text] [Related]
4. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibition with resorcyclic acid lactones (RALs).
Winssinger N; Fontaine JG; Barluenga S
Curr Top Med Chem; 2009; 9(15):1419-35. PubMed ID: 19860733
[TBL] [Abstract][Full Text] [Related]
6. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
7. The 'active life' of Hsp90 complexes.
Prodromou C
Biochim Biophys Acta; 2012 Mar; 1823(3):614-23. PubMed ID: 21840346
[TBL] [Abstract][Full Text] [Related]
8. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
9. Review: The HSP90 molecular chaperone-an enigmatic ATPase.
Pearl LH
Biopolymers; 2016 Aug; 105(8):594-607. PubMed ID: 26991466
[TBL] [Abstract][Full Text] [Related]
10. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
Prodromou C
Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
13. Hsp90: Friends, clients and natural foes.
Verma S; Goyal S; Jamal S; Singh A; Grover A
Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
[TBL] [Abstract][Full Text] [Related]
14. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.
Ardi VC; Alexander LD; Johnson VA; McAlpine SR
ACS Chem Biol; 2011 Dec; 6(12):1357-66. PubMed ID: 21950602
[TBL] [Abstract][Full Text] [Related]
15. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
16. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 molecular chaperone inhibitors: are we there yet?
Neckers L; Workman P
Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
20. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
